The global antibody therapy market size surpassed USD 240.90 billion in 2023 and is projected to rake around USD 737.59 billion by 2033 growing at a CAGR of 11.84% from 2024 to 2033.
Key Points
- North America dominated the market with a major market share of 34% in 2023.
- By type, the monoclonal antibody segment held the largest market share in 2023.
- By end user, the hospital segment has captured the largest market share of 48% in 2023.
The Antibody Therapy market has witnessed significant growth in recent years, driven by the increasing prevalence of chronic diseases and a growing aging population. Antibody therapy, a form of immunotherapy, utilizes the body’s natural immune system to fight diseases. This market is characterized by the development and utilization of monoclonal antibodies (mAbs) that specifically target and neutralize disease-causing agents. The therapeutic potential of antibody-based drugs has led to a surge in research and development activities, making it a key player in the pharmaceutical and biotechnology sectors.
The global Antibody Therapy market is multifaceted, covering a wide range of therapeutic areas such as oncology, autoimmune disorders, infectious diseases, and cardiovascular diseases. The rising incidence of cancer and autoimmune disorders has spurred the demand for targeted and personalized therapies, where antibody therapy plays a pivotal role. Moreover, the robust pipeline of novel antibody-based drugs and ongoing clinical trials contribute to the market’s dynamic landscape.
Get a Sample: https://www.precedenceresearch.com/sample/3891
Growth Factors
- Advancements in Biotechnology: The continuous advancements in biotechnology have propelled the development of innovative antibody-based therapies. Cutting-edge technologies, such as recombinant DNA and hybridoma techniques, have paved the way for the generation of high-quality monoclonal antibodies with enhanced specificity and reduced side effects.
- Increasing Prevalence of Chronic Diseases: The escalating global burden of chronic diseases, including cancer, rheumatoid arthritis, and diabetes, has driven the demand for effective and targeted therapeutic solutions. Antibody therapy, with its ability to specifically target disease markers, has emerged as a promising treatment option, fostering market growth.
- Collaborations and Partnerships: The pharmaceutical industry has witnessed a surge in collaborations and partnerships between key market players. These alliances aim to leverage complementary strengths in research, development, and commercialization, expediting the introduction of novel antibody-based drugs into the market.
- Rising Healthcare Expenditure: As global healthcare expenditure continues to rise, there is an increased willingness among patients and healthcare providers to adopt advanced and expensive therapies, including antibody-based treatments. This financial commitment contributes to the growth of the Antibody Therapy market.
Regions Snapshot
North America: The North American region dominates the Antibody Therapy market, owing to a well-established healthcare infrastructure, high healthcare expenditure, and a robust biotechnology sector. The presence of major pharmaceutical companies and ongoing research activities contribute to the region’s prominence.
Europe: Europe is a significant market for antibody therapy, characterized by a strong emphasis on research and development. The region’s favorable regulatory environment and increasing awareness of personalized medicine further support market growth.
Asia-Pacific: The Asia-Pacific region is witnessing rapid growth in the Antibody Therapy market, driven by the increasing prevalence of chronic diseases and a rising focus on healthcare infrastructure development. Emerging economies, such as China and India, are becoming key players in the production and consumption of antibody-based drugs.
Latin America and the Middle East: These regions are experiencing a gradual uptake of antibody therapy, propelled by improving healthcare facilities, increasing awareness, and a growing patient population.
Antibody Therapy Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 11.84% |
| Global Market Size in 2023 | USD 240.90 Billion |
| Global Market Size by 2033 | USD 737.59 Billion |
| U.S. Market Size in 2023 | USD 57.33 Billion |
| U.S. Market Size by 2033 | USD 175.55 Billion |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Type and By End User |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
SWOT Analysis
Strengths:
- Specific Targeting: Antibody therapy offers high specificity, targeting disease-specific markers while minimizing damage to healthy cells.
- Diverse Therapeutic Applications: The versatility of antibody therapy allows its application in various therapeutic areas, contributing to a broad market scope.
- Collaborations and Partnerships: Strong collaborations among pharmaceutical companies and research institutions enhance the development and commercialization of antibody-based drugs.
Weaknesses:
- High Costs: The cost of developing and producing monoclonal antibodies is high, potentially limiting accessibility for certain patient populations.
- Complex Manufacturing Process: The intricate manufacturing process of monoclonal antibodies may pose challenges in scaling up production.
Opportunities:
- Expanding Therapeutic Applications: Ongoing research is exploring new therapeutic applications for antibody therapy, presenting opportunities for market expansion.
- Emerging Markets: The untapped potential in emerging markets provides opportunities for market players to establish a strong foothold and cater to the growing healthcare needs.
Threats:
- Biosimilar Competition: The emergence of biosimilars poses a threat to the Antibody Therapy market, as these alternatives may offer cost-effective options.
- Stringent Regulatory Requirements: Strict regulatory requirements and the lengthy approval process may hinder the timely introduction of new antibody-based drugs to the market.
Read Also: Atherectomy Devices Market Size to Hold USD 1,512.89 Mn by 2033
Recent Developments
- In July 2022, AstraZeneca acquired TeneoTwo, strengthening its hematological cancer pipeline with a clinical-stage T-cell engager.
- In December 2023, Bristol Myers Squibb augmented its radiopharmaceutical platform with the acquisition of RayzeBio.
- In June 2022, Galapagos acquired CellPoint and AboundBio to accelerate access to next-generation cell therapies.
- In June 2023, Lilly acquired cancer antibody drug startup Emergence.
- In September 2021, Boehringer Ingelheim acquired Abexxa Biologics to expand its research efforts in cancer immunology and novel immunotherapeutic approaches further.
- In June 2023, Lonza announced the acquisition of Synaffix, strengthening its antibody-drug conjugates offering.
Antibody Therapy Market Companies
- Bristol-Myers Squibb
- GlaxoSmithKline plc
- Takeda Pharmaceuticals
- Eli Lilly and Company
- Merck & Co, Inc.
- Seagen, Johnson & Johnson
- Novartis AG
- Regeneron Pharmaceuticals
- F. Hoffmann-La Roche Ltd.
- Merck & Co, IncSeagen
Segments Covered in the Report
By Type
- Monoclonal Antibodies
- Oncology, Autoimmune Disease
- Infectious Disease
- Other
- Antibody Drug Conjugates
By End User
- Hospitals
- Specialty Centers
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/
